📇 Rhumatologue · LE FRANCOIS · (972) · Hospitalier

MME MYRIAM M'PAY

Pourquoi vous devez consulter ce praticien

2 raisons identifiées

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche
Délais de RDV courts dans la région
106.4 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 LE FRANCOIS (972)HospitalierRPPS 10001669380

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

CENTRE HOSPITALIER ERNEST WAN-AJOUHU
LOT POINTE COURCHET BP 56, 97240 LE FRANCOIS
☎ 0596301099Activité de soin et de pharmacie🏥 Centre CH ↗

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Mobile applications in oncology: A systematic review of health science databases

International journal of medical informatics · 2020

📚 31 citations🎯 RCR 2.28Top 23% NIH🔓 Open Access📄 PDF gratuit ↗

Resveratrol restores the level of key inflammatory cytokines and RANKL/OPG ratio in the femur of rat osteoporosis model

Journal of women & aging · 2019

📚 21 citations🎯 RCR 1.23

Phase IV postmarketing surveillance study shows continued efficacy and safety of Stempeucel in patients with critical limb ischemia due to Buerger's disease

Stem cells translational medicine · 2021

📚 17 citations🎯 RCR 1.35🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Buerger's disease or thromboangiitis obliterans is a type of obstructive vascular diseases categorized as vasculitis and usually present in 95% of young smoker men. The main pathogenetic mechanism is interplay between immune system and inflammation. Earlier our phase II study has shown that Stempeucel is safe when injected at 2 million cells/kg body weight by virtue of its anti-inflammatory, immunomodulatory, and angiogenetic properties. The present study was conducted to further assess the safety and efficacy of Stempeucel in critical limb ischemia due to Buerger's disease after obtaining approval from Indian FDA based on the data generated in the phase II study. This is an open label, multicenteric phase IV PMS study conducted across India with experienced vascular surgeons. Fifty patients of critical limb ischemia due to Buerger's disease with Rutherford III-5 or III-6 were included in the study and each individual received a dose of 2 million cells/kg body weight of Stempeucel in the calf muscles and around the ulcer. These patients were evaluated over 12 months from drug administration. The present study showed the continued long term efficacy over a period of 12 months follow up in these patients corroborating the result obtained in the previous phase II studies. There was significant improvement in rest pain, ankle systolic pressure, and ankle brachial pressure index with accelerated ulcer healing. In conclusion, the present study shows that the intramuscular administration of Stempeucel continues to be safe, tolerable, and effective alternative treatment in patients with Buerger's disease.

Cookies & analyse de trafic

MME MYRIAM M'PAY

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal25

Revue générale3

Arthrite juvénile2

Épidémiologie & registres2

Qualité de vie / PROMs2

Vascularites des gros vaisseaux2

Case report / série1

csDMARDs1

Économie santé1

Essai clinique1

Génétique1

Gériatrie1

JAK inhibiteurs1

Lombalgie1

Lupus1

Maladie à IgG41

Revue / méta-analyse1

Risque cardio-vasculaire1

Santé mentale / fatigue1

Sjögren1

Tendinopathies & SCC1

Vascularites1

Vraie vie / RWE1

Partager cette fiche